EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients

Jelena Jelicic iD, Karen Juul-Jensen, Zoran Bukumiric, Mikkel Runason Simonsen, Michael Roost Clausen iD, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Anne Ortved Gang, Peter Brown, Tarec Christoffer El-Galaly, Thomas Stauffer Larsen

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Jelena Jelicic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Registries, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Recent front‐line clinical trials used the International Prognostic Index (IPI) to identify trial‐eligible patients with newly diagnosed diffuse large B‐cell lymphoma (DLBCL). However, many IPI‐like variants with improved accuracy have been developed over the years for rituximab‐treated patients.

Methods

We assessed the impact of International Prognostic Indices on patient enrolment in clinical trials, aiming to exclude low‐risk IPI patients based on POLARIX/EPCORE DLBCL‐2 trial criteria.

Results

We identified 2877 patients in the Danish Lymphoma Registry who would have been eligible for the POLARIX trial if patients with IPI 0–1 scores were included. IPI and NCCN‐IPI assigned 33.3% and 11.9% of patients to the low‐risk group, respectively. Shorter 5‐year overall survival (91.4% vs. 97.5%), higher relapse rate (9.9% vs. 4.4%), and more deaths (16.1% vs. 4.4%) occurred in the low‐risk IPI group compared with low‐risk NCCN‐IPI group. Analyzed models failed to identify true high‐risk patients with poor prognosis. Similar results were found in the confirmatory cohort developed based on EPCORE DLBCL‐2 trial eligibility criteria.

Conclusion

True low‐risk patients are more optimal identified by NCCN‐IPI and should be excluded from front‐line clinical trials due to their excellent prognosis. However, additional high‐risk factors besides clinical prognostic models need to be considered when selecting trial‐eligible patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseRegistriesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemalePrognosisMiddle AgedAgedAdultAged, 80 and overClinical Trials as TopicPatient SelectionRituximabDenmark

Stichwörter der Autor:innen

clinical trialdiffuse large B cell lymphomaprognostic modelsselection criteria

Substanzen

Rituximab

Autor:innen und Institutionen

  • Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Institute for Medical Statistics and Informatics, University of Belgrade, Faculty of Medicine, Belgrade, Serbia.
  • Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark.
  • Department of Hematology, Vejle Hospital, Sygehus Lillebaelt, Vejle, Denmark.
  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Jelena Jelicic, Michael Roost Clausen

Zitieren

APA

Jelicic, J., Juul-Jensen, K., Bukumiric, Z., Runason Simonsen, M., Roost Clausen, M., Ludvigsen Al-Mashhadi, A., Schou Pedersen, R., Bjørn Poulsen, C., Ortved Gang, A., Brown, P., El-Galaly, T. C., & Stauffer Larsen, T. (2025). A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients. European Journal of Haematology. https://doi.org/10.1111/ejh.14301

Vancouver

Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, et al. A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients. European Journal of Haematology. 2025. doi:10.1111/ejh.14301

BibTeX
@article{Jelicic2025,
  author = {Jelicic, Jelena and Juul-Jensen, Karen and Bukumiric, Zoran and Runason Simonsen, Mikkel and Roost Clausen, Michael and Ludvigsen Al-Mashhadi, Ahmed and Schou Pedersen, Robert and Bjørn Poulsen, Christian and Ortved Gang, Anne and Brown, Peter and El-Galaly, Tarec Christoffer and Stauffer Larsen, Thomas},
  title = {A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14301}
}
Kostenlos starten →